Scarica l'app Stockscreener
0.00
100.00%
-8.68
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAGE Giù?
Forum
Previsione
Precedente Chiudi:
$8.68
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$544.94M
Reddito:
$91.06M
Utile/perdita netta:
$-503.14M
Rapporto P/E:
0.00
EPS:
-8.39
Flusso di cassa netto:
$-424.74M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$9.36
Sage Therapeutics Inc Stock (SAGE) Company Profile
Nome
Sage Therapeutics Inc
Settore
Industria
Telefono
617-299-8380
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Confronta SAGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
0.00 | 544.94M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-11 | Ripresa | BofA Securities | Underperform |
| 2024-11-21 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-29 | Iniziato | Citigroup | Sell |
| 2024-05-29 | Iniziato | Robert W. Baird | Neutral |
| 2024-04-17 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-08-08 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | Downgrade | Goldman | Buy → Neutral |
| 2023-08-08 | Downgrade | Needham | Buy → Hold |
| 2023-08-07 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-08-07 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-08-07 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | Downgrade | Stifel | Buy → Hold |
| 2023-08-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-03-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-03-31 | Iniziato | Berenberg | Hold |
| 2021-11-02 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-16 | Downgrade | Citigroup | Buy → Neutral |
| 2021-04-07 | Iniziato | Piper Sandler | Overweight |
| 2021-02-26 | Downgrade | Mizuho | Buy → Neutral |
| 2021-02-25 | Reiterato | H.C. Wainwright | Neutral |
| 2021-02-02 | Ripresa | Raymond James | Mkt Perform |
| 2021-01-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-01-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | Reiterato | H.C. Wainwright | Neutral |
| 2020-09-11 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-08-10 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-04-08 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-28 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-06 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-12-05 | Reiterato | Guggenheim | Buy |
| 2019-12-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-10-30 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-23 | Iniziato | Wedbush | Outperform |
| 2019-04-25 | Iniziato | Jefferies | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Sage Therapeutics Inc Borsa (SAGE) Ultime notizie
Postpartum Depression Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers - Barchart.com
How Sage Therapeutics Inc. stock compares to industry benchmarksInsider Selling & Free Expert Verified Stock Movement Alerts - Newser
Will Sage Therapeutics Inc. (SG7) stock enhance shareholder valueJuly 2025 Review & Technical Pattern Alert System - Newser
How big funds are accumulating Sage Therapeutics Inc. (SG7) stockStop Loss & Precise Swing Trade Alerts - Newser
Will Sage Therapeutics Inc. (SG7) stock outperform small cap peersDip Buying & Long-Term Safe Investment Ideas - Newser
Why Sage Therapeutics Inc. stock remains a top recommendationJuly 2025 Closing Moves & Safe Entry Zone Tips - Newser
How Sage Therapeutics Inc. (SG7) stock benefits from digital adoptionJuly 2025 Selloffs & Breakout Confirmation Trade Signals - Newser
What is the fair value of Sage Therapeutics Inc. stock now2025 Momentum Check & Consistent Profit Trading Strategies - Newser
Is Sage Therapeutics Inc. stock a buy on dips2025 Breakouts & Breakdowns & AI Enhanced Trading Alerts - BỘ NỘI VỤ
What analysts say about Sage Therapeutics Inc stockInsider Trading Compliance & High Return Wealth Building - earlytimes.in
Is Sage Therapeutics Inc. (SG7) stock undervalued after correctionWeekly Gains Summary & Real-Time Volume Spike Alerts - newser.com
What technical patterns form on Sage Therapeutics Inc. (SG7) stock chartsRate Cut & Weekly Market Pulse Updates - newser.com
How Sage Therapeutics Inc. stock benefits from global expansionJuly 2025 Drop Watch & Advanced Technical Signal Analysis - newser.com
Can Sage Therapeutics Inc. (SG7) stock resist broad market declines2025 Trading Recap & AI Forecast for Swing Trade Picks - newser.com
Is Sage Therapeutics Inc. (SG7) stock a buy during volatile marketsTrade Entry Report & Weekly Setup with ROI Potential - newser.com
Can Sage Therapeutics Inc. (SG7) stock sustain revenue momentumWeekly Profit Analysis & Fast Entry Momentum Alerts - newser.com
Sage Therapeutics Inc. stock momentum explainedJuly 2025 WrapUp & Fast Gain Stock Tips - newser.com
Sage Therapeutics Inc. stock prediction for this weekWeekly Trade Summary & Consistent Profit Focused Trading Strategies - newser.com
Will Sage Therapeutics Inc. benefit from macro trends2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Will Sage Therapeutics Inc. (SG7) stock beat value stocks2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
Why Sage Therapeutics Inc. (SG7) stock stays on top picks2025 Volatility Report & Precise Swing Trade Entry Alerts - newser.com
How Sage Therapeutics Inc. stock compares to growth peers2025 Technical Patterns & Growth Focused Stock Pick Reports - newser.com
Will Sage Therapeutics Inc. stock recover after recent dropWeekly Risk Report & Capital Efficiency Focused Strategies - newser.com
Published on: 2025-11-16 05:15:30 - newser.com
Sage Therapeutics Inc SG7 Stock Analysis and ForecastEarnings Revision Updates & Free Stock Trading Workshops - earlytimes.in
Sage Therapeutics Inc Azioni (SAGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):